Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385138
Status:
TERMINATED
Last Update Posted:
2014-05-05
First Post:
2006-10-04
Brief Title:
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition
Sponsor:
The Medicines Company
Organization:
The Medicines Company
Study Overview
Official Title:
A Clinical Trial Comparing Treatment With Cangrelor in Combination With Usual Care to Usual Care in Subjects Who Require Percutaneous Coronary Intervention PCI
Status:
TERMINATED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Insufficient evidence of the clinical effectiveness of cangrelor
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Platform
Brief Summary:
The primary objective of this study is to demonstrate that the efficacy of cangrelor combined with usual care is superior to that of usual care in subjects requiring percutaneous coronary intervention PCI as measured by a composite of all-cause mortality myocardial infarction MI and ischemia-driven revascularization IDR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None